🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "significant breakthrough" in the fight against superbug strains of the infection, according to health experts.

An International Health Concern

The sexually transmitted infection are escalating around the world, with figures suggesting in excess of 82 million new cases each year. Especially elevated rates are seen in Africa and countries within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. Across England, cases have reached a all-time high, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an important and timely step in the face of growing infection rates, escalating drug resistance and the highly restricted therapeutic options at this time.”

Public health authorities are increasingly worried about the rise in antibiotic-resistant strains. The global health body has classified it as a "priority pathogen". Recent surveillance revealed that resistance to primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Drugs Receive Clearance

Zoliflodacin, alternatively called a brand name, was cleared by the American regulatory agency in December for combating gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Scientists hope that focused deployment of this new drug will help hinder the emergence of superbugs.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, gained clearance in concurrent days. This drug, which is also used to treat urinary tract infections, was demonstrated in studies to be able to combat superbug versions of the gonorrhoea bacteria.

An Innovative Approach to Creation

This new treatment emerged from a unique collaborative effort for drug creation. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company its industry partner to bring it to fruition.

“This milestone signifies a huge turning point in the therapy of multidrug-resistant gonorrhoea, which up to this point has been outpacing medical innovation.”

Research Study Outcomes and Worldwide Availability

Based on findings released by a major medical journal, the new drug cured the vast majority of cases of the STI. This establishes an comparable level with the existing first-line therapy, which combines two antibiotics. The research involved hundreds of volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, the non-profit has the rights to register and commercialise the drug in a wide range of regions with limited resources.

Doctors treating patients have expressed optimism. Access to a one-pill regimen like this is seen as a "critical tool" for managing the epidemic. This is considered crucial to reduce the burden of the infection for people and to stop the proliferation of untreatable gonorrhoea globally.